Citadel Advisors
ADVM

Citadel Advisors’s Adverum Biotechnologies ADVM Stock Holding History

Citadel Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,267
Closed -$78.2K – 12534
2025
Q3 		$78.2K Sell
17,267
-61,004
-78% -$180K ﹤0.01% 11988
2025
Q2 		$168K Buy
+78,271
New +$219K ﹤0.01% 10850
2025
Q1 		– Sell
-149,071
Closed -$672K – 14383
2024
Q4 		$696K Buy
149,071
+125,537
+533% +$845K ﹤0.01% 7844
2024
Q3 		$165K Sell
23,534
-102,256
-81% -$743K ﹤0.01% 10432
2024
Q2 		$863K Buy
+125,790
New +$1.17M ﹤0.01% 6888
2024
Q1 		– Sell
-3,371
Closed -$25.4K – 14474
2023
Q4 		$25.4K Buy
+3,371
New +$30.8K ﹤0.01% 12412
2023
Q2 		– Sell
-422
Closed -$3.03K – 14261
2023
Q1 		$3.03K Sell
422
-380
-47% -$2.69K ﹤0.01% 14079
2022
Q4 		$4.65K Sell
802
-492
-38% -$3.73K ﹤0.01% 14079
2022
Q3 		$12K Sell
1,294
-1,234
-49% -$16.2K ﹤0.01% 12219
2022
Q2 		$31K Sell
2,528
-5,179
-67% -$54.3K ﹤0.01% 12193
2022
Q1 		$101K Sell
7,707
-20,461
-73% -$299K ﹤0.01% 12271
2021
Q4 		$496K Buy
28,168
+3,266
+13% +$65.4K ﹤0.01% 9713
2021
Q3 		$540K Sell
24,902
-4,710
-16% -$120K ﹤0.01% 9676
2021
Q2 		$1.04M Sell
29,612
-9,850
-25% -$531K ﹤0.01% 8283
2021
Q1 		$3.89M Buy
39,462
+9,840
+33% +$1.18M ﹤0.01% 4828
2020
Q4 		$3.21M Sell
29,622
-12,632
-30% -$1.56M ﹤0.01% 4479
2020
Q3 		$4.35M Sell
42,254
-44,159
-51% -$6.61M ﹤0.01% 3355
2020
Q2 		$18M Sell
86,413
-27,891
-24% -$4.94M 0.01% 1592
2020
Q1 		$11.2M Buy
114,304
+87,908
+333% +$10.2M 0.01% 1740
2019
Q4 		$3.04M Sell
26,396
-57,676
-69% -$5.08M ﹤0.01% 3770
2019
Q3 		$4.58M Buy
84,072
+82,199
+4,389% +$9.26M ﹤0.01% 3234
2019
Q2 		$223K Sell
1,873
-172
-8% -$14.2K ﹤0.01% 8031
2019
Q1 		$107K Sell
2,045
-149,476
-99% -$6.04M ﹤0.01% 8526
2018
Q4 		$4.77M Buy
151,521
+69,866
+86% +$2.84M ﹤0.01% 2852
2018
Q3 		$4.94M Sell
81,655
-123,380
-60% -$6.93M ﹤0.01% 3023
2018
Q2 		$10.9M Buy
205,035
+67,567
+49% +$4.06M 0.01% 1848
2018
Q1 		$7.97M Buy
137,468
+132,749
+2,813% +$8.27M ﹤0.01% 1944
2017
Q4 		$165K Buy
4,719
+3,704
+365% +$122K ﹤0.01% 7225
2017
Q3 		$37K Buy
+1,015
New +$28.2K ﹤0.01% 7246
2016
Q4 		– Sell
-1,400
Closed -$58K – 7180
2016
Q3 		$58K Buy
+1,400
New +$53.1K ﹤0.01% 6822
2015
Q4 		– Sell
-83
Closed -$7K – 8668
2015
Q3 		$7K Sell
83
-1,948
-96% -$249K ﹤0.01% 8564
2015
Q2 		$330K Buy
2,031
+1,232
+154% +$416K ﹤0.01% 5611
2015
Q1 		$324K Sell
799
-4,005
-83% -$1.69M ﹤0.01% 5540
2014
Q4 		$2.59M Buy
4,804
+172
+4% +$66.3K ﹤0.01% 2623
2014
Q3 		$1.58M Buy
+4,632
New +$1.38M ﹤0.01% 3132

Citadel Advisors's ADVM Position: Q4 2025 in Review

Citadel Advisors sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 17,267 shares — an estimated $78.2K sold.

Citadel Advisors first reported a position in ADVM in Q3 2014 and held it in 35 quarters. The position peaked at $18M in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.

  • Citadel Advisors reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 17,267 Adverum Biotechnologies shares in Q4 2025, an estimated $78.2K.
  • Citadel Advisors first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 35 quarters.
  • Citadel Advisors's Adverum Biotechnologies position peaked at $18M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.